Resonance Health is a healthcare company listed on the Australian Stock Exchange (ASX:RHT). Resonance Health provides quantitative MRI based technologies for the diagnosis and monitoring of human disease. Accurate imaging end points are increasingly used in clinical trials, providing quantitative and direct evidence for regulatory submissions.

Resonance Health's image analysis laboratory provides quality certified central image analysis services to the clinical community and to clinical trials.

FerriScan® was the first product brought to market and provides an accurate non-invasive assessment of liver iron, largely removing the need for a liver biopsy in many patients with iron overload conditions.

HepaFat-Scan® gained FDA clearance in December 2013 for the measurement of fatty liver and development of an MRI based method to assess liver fibrosis continues as part of the Company's focus on developing diagnostic products to address liver disease.

Registered Office and Principal Place of Business:

141 Burswood Road
Burswood Western Australia 6100

Postal Address

PO Box 71
Burswood Western Australia 6909

Contact details:

T +61 8 9286 5300
F +61 8 9286 1179
E
W www.resonancehealth.com

Investor Enquiries:

Adrian Bowers

T +61 8 9286 5300
E

Auditors

HLB Mann Judd

Level 4
130 Stirling Street
Perth Western Australia 6000

Resonance Health’s Principal Share Registry:

Advanced Share Registry Services

110 Stirling Hwy
Nedlands Western Australia 6009

T +61 8 9389 8033
F +61 8 9262 3723

Corporate Governance Statement